- Home
- SEER vs TCRX Comparison
SEER vs TCRX Comparison
Compare SEER & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEER
- TCRX
- Stock Information
- Founded
- SEER 2017
- TCRX 2018
- Country
- SEER United States
- TCRX United States
- Employees
- SEER N/A
- TCRX N/A
- Industry
- SEER Medicinal Chemicals and Botanical Products
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SEER Health Care
- TCRX Health Care
- Exchange
- SEER Nasdaq
- TCRX Nasdaq
- Market Cap
- SEER 113.8M
- TCRX 91.7M
- IPO Year
- SEER 2020
- TCRX 2021
- Fundamental
- Price
- SEER $2.04
- TCRX $1.69
- Analyst Decision
- SEER
- TCRX Strong Buy
- Analyst Count
- SEER 0
- TCRX 5
- Target Price
- SEER N/A
- TCRX $9.40
- AVG Volume (30 Days)
- SEER 134.9K
- TCRX 215.6K
- Earning Date
- SEER 11-05-2025
- TCRX 11-11-2025
- Dividend Yield
- SEER N/A
- TCRX N/A
- EPS Growth
- SEER N/A
- TCRX N/A
- EPS
- SEER N/A
- TCRX N/A
- Revenue
- SEER $16,288,000.00
- TCRX $6,961,000.00
- Revenue This Year
- SEER $27.77
- TCRX $255.18
- Revenue Next Year
- SEER $20.28
- TCRX N/A
- P/E Ratio
- SEER N/A
- TCRX N/A
- Revenue Growth
- SEER 10.52
- TCRX N/A
- 52 Week Low
- SEER $1.62
- TCRX $1.02
- 52 Week High
- SEER $2.63
- TCRX $6.23
- Technical
- Relative Strength Index (RSI)
- SEER 46.20
- TCRX 41.04
- Support Level
- SEER $1.97
- TCRX $1.73
- Resistance Level
- SEER $2.10
- TCRX $1.96
- Average True Range (ATR)
- SEER 0.05
- TCRX 0.11
- MACD
- SEER 0.00
- TCRX -0.02
- Stochastic Oscillator
- SEER 43.75
- TCRX 10.00
About SEER Seer Inc.
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid, and large-scale access across the proteome.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.